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Abstract
Background: Familial adenomatous polyposis (FAP) is an autosomal dominant colorectal tumor characterized by
numerous adenomatous colonic polyps that often lead to colon cancer. Although most patients with FAP harbored
germline mutations in APC gene, it was recently recognized that patients with clinical FAP, but without detectable
pathogenic mutations, could be associated with somatic mosaic APC mutation.
Methods: We reanalyzed the nest-generation sequencing (NGS) gene panel testing results of patients who were
diagnosed with FAP, but did not have APC mutations, at Yonsei Cancer Prevention Center between July 2016 and
March 2018. We tested several variant calling algorithms to identify low level mosaic variants. In one patient with a
low frequency APC mutation, NGS analysis was performed together with endoscopic biopsy. Variant calling tools
HaplotypeCaller, MuTect2, VarScan2, and Pindel were used. We also used 3′-Modified Oligonucleotides (MEMO)-PCR
or conventional PCR for confirmation.
Results: Among 28 patients with clinical suspicion of FAP but no detectable pathogenic variants of colonic polyposis
associated genes, somatic mosaic pathogenic variants were identified in seven patients. The variant allele frequency
ranged from 0.3 to 7.7%. These variants were mostly detected through variant caller MuTect2 and Pindel, and were
further confirmed using mutant enrichment with MEMO-PCR.
Conclusions: The NGS with an adequate combination of bioinformatics tools is effective to detect low level somatic
variants in a single assay. Because mosaic APC mutations are more frequent than previously thought, the presence of
mosaic mutations must be considered when analyzing genetic tests of patients with FAP.
Keywords: Next-generation sequencing, APC, Somatic mosaic mutation, Familial adenomatous polyposis, Colorectal
cancer
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: TAEILKIM@yuhs.ac; LEE.ST@yuhs.ac
†Borahm Kim and Dongju Won contributed equally to this work.
3Department of Internal Medicine and Institute of Gastroenterology, Brain
Korea 21 PLUS Project for Medical Sciences Yonsei Cancer Prevention Center,
Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul
03722, Republic of Korea
1Department of Laboratory Medicine, Yonsei University College of Medicine,
50 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea
Full list of author information is available at the end of the article
Kim et al. BMC Medical Genomics          (2019) 12:103 
https://doi.org/10.1186/s12920-019-0553-0
Background
Familial adenomatous polyposis (FAP, OMIM#175100) is
an autosomal dominant colorectal tumor syndrome char-
acterized by numerous adenomatous colonic polyps that
are prone to progress to colon cancer. The majority of pa-
tients with FAP harbor a germline mutation in the APC
gene on chromosome 5q21. A few other genes, such as
MUTYH, POLD1, and POLE, are also associated with
hereditary colonic polyposis [1–4]. However, one-fifth of
patients with FAP are apparently sporadic without any fa-
milial history [5, 6]. It has been widely recognized that
some of these sporadic FAP patients have somatic mosaic
APC mutations [5–12].
Conventionally, genetic tests for hereditary cancer are
performed with leukocyte DNA using PCR and Sanger
sequencing. Unlike germline mutations, somatic muta-
tions show various mutant allele frequencies in leuko-
cytes. As a result, a small fraction of mosaic mutations
are missed in routine genetic analyses optimized for
germline variants, partly due to limited sensitivity of the
testing method.
Next-generation sequencing (NGS) has been rapidly
adopted in the clinical field. In combination with exten-
sive bioinformatics analysis, NGS can identify a wide
range of variants in a single assay, including single
nucleotide variations (SNVs), small to large insertions or
deletions (indels), and copy number variations. Further-
more, with higher sensitivity, NGS may identify previ-
ously undetected variants. Nevertheless, identifying
somatic mutations with small variant allele frequencies
(VAFs) requires careful consideration throughout the en-
tire process of acquiring sequencing data, choosing ana-
lytic tools, and interpreting final results.
Here, we analyzed peripheral blood samples from pa-
tients with unexplained FAP using NGS to estimate the
frequency of somatic mosaic mutations in the APC gene.
We also sought to determine appropriate bioinformatics
algorithms for detecting mutations in the APC gene with
small VAFs in peripheral blood.
Method
Patients and samples
Among patients who underwent NGS for hereditary
cancer between July 2016 and March 2018, 53 were sus-
picious for FAP on colonoscopy (Table 1). A list of genes
included in the NGS panel is provided in Additional file 1:
Table S1. Among these 53 patients, 28 were without de-
tectable pathogenic variants in colonic polyposis associ-
ated genes (i.e., APC, MUTYH, POLE, and POLD1), and
they were subjected to further bioinformatics analysis. If
available, colonic polyp specimens obtained during col-
onoscopy were analyzed. Written informed consent was
obtained for all patients. The current study was ap-
proved by our institutional review board.
DNA extraction and sequencing
Genomic DNA was extracted from peripheral blood
using the QIAamp DNA Blood Mini Kit (Qiagen, Venlo,
The Netherlands). For paraffin-embedded tissue sam-
ples, Maxwell® RSC DNA FFPE Kits (Promega, Madison,
WI, USA) were used to extract genomic DNA. The
amount of input DNA was approximately 500 ng. DNA
was fragmented to segments between 150 and 250 bp
using the Bioruptor® Pico Sonication System (Diagenode,
Liege, Belgium) and then end-repaired and ligated to
Illumina adapters (Illumina, San Diego, CA, USA) and
indices. Sequencing libraries were then hybridized with
capture probes (Celemic, Seoul, Korea). Enriched DNA
was then amplified, and clusters were generated and se-
quenced on a NextSeq 550 instrument (Illumina) with
2 × 151 bp reads. All procedures were performed per the
manufacturers’ instructions.
Data analysis and interpretation
The Burrows-Wheeler alignment tool (0.7.12) was used
to align reads to human genomic reference sequences
(GRCh37) [13]. To identify SNVs and indels, the Haplo-
typeCaller in the genome analysis tool kit (GATK) pack-
age (3.8–0) was used [14]. All mutations were annotated
using ANNOVAR and VEP (87) software [15, 16]. De-
tected variants were further examined by visual verifica-
tion using the Integrative Genomic Viewer (IGV) [17].
Variants confirmed to be true-positive were further veri-
fied by searching the literature and databases.
In addition to HaplotypeCaller and MuTect2 in GATK
(3.8–0) and VarScan2 (2.4.0) were used for further bio-
informatics analysis of patients without mutations [18,
19]. To detect medium to large indels, Pindel (0.2.0) was
used [20], and results from the four algorithms were
compared.
Table 1 Patients with clinical suspicion of familial adenomatous
polyposis and mutation characteristics
Total 53
Phenotype
Typical FAP 18
Attenuated FAP 35
Age of onset 39 (19–81)
Gene panel results
Pathogenic APC variants 25
Sequence variation 23
Deletion or duplication 2
Patients without pathogenic variants 28
Further analysis
Mosaicism 7
Unexplained 21
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Confirmation test
Low level variants in two patients were further confirmed
using conventional PCR and Sanger sequencing. Two pa-
tients with VAFs on below the detection limit of conven-
tional tests were subjected to mutant enrichment with 3′-
modified oligonucleotides (MEMO)-PCR, followed by
Sanger sequencing, which is based on the use of a 3’modi-
fied oligonucleotide primer that blocks extension of the
normal allele but enables extension of the mutated allele
[21]. Primers used in MEMO–PCR are shown in Add-
itional file 1: Table S2. For another two patients, Sanger
sequencing of colonic polyp specimens was performed.
Results
Patients and NGS statistics
There were 53 patients with a clinical diagnosis of FAP,
and 25 pathogenic variants in APC were discovered by
NGS for hereditary cancer panel using HaplotypeCaller.
Among variants, 23 were sequence variations, and two
were partial deletions. They all had VAFs around 0.5 sug-
gestive of germline origin (Additional file 1: Table S3). In
the remaining 28 patients, no pathogenic or likely patho-
genic variants were observed upon NGS: They comprised
patients with a large number of colonic polyps identified
on colonoscopy, but no family history of disease associ-
ated with colonic polyps (Table 2). One patient had a fam-
ily history of maternal rectal cancer, although the cancer
was not of polyposis type and was diagnosed at the age of
70 years, which can hardly be seen to be associated with
APC gene mutation. After reanalysis with additional vari-
ant calling tools, seven mosaic mutations in APC were de-
tected in seven patients, comprising 13.2% (7/53) of all
patients suspicious for FAP (Table 2). The median depth
of coverage in the gene panel was 691×, with a maximum
depth of 7976×. The median depth of coverage for APC
was 2877×, ranging from 2185× to 4076 × .
Somatic variant detection depends on bioinformatics
tools
Somatic mosaic mutations detected in APC are summa-
rized in Table 2. An additional seven somatic mosaic
pathogenic variants were identified by further analysis of
sequencing data with MuTect2, VarScan2, and Pindel.
The seven mutations are known to cause FAP. Five in-
sertion/deletions resulting in a frameshift mutation were
identified by both MuTect2 and Pindel tools, and two
nonsense variants went undetected by Pindel, as would
be expected. The VAFs thereof range from 0.3 to 7.7%.
Only two variants (P2 and P6) with relatively high VAFs
were detected by VarScan2, and none of the variants
with a VAF below 10% were detected by HaplotypeCal-
ler. All variants were identified by IGV (Fig. 1).
Colonic polyp samples from a patient (P1) were sub-
jected to NGS analysis. As shown in Table 2, a somatic
mutation found in leukocytes was enriched in the co-
lonic polyp from 7 to 20%, which confirmed the causa-
tive effect of the mutation.
Confirmation test
Six of the seven somatic variants were further confirmed
by a second method (Table 2 and Fig. 1). From patients
P1 to P5, variants went undetected by conventional PCR
and sequencing using DNA from leukocytes because of
low VAF; two variants (P6 and P7) of relatively high VAF
were identified by conventional Sanger sequencing. Two
pathogenic variants (P1 and P2) were further confirmed
using MEMO-PCR, followed by Sanger sequencing. For
P3 and P5, colonic polyp specimens were sequenced by
conventional PCR and sequencing to confirm the effect
of mutations, and suggested that the causative mutations
had been enriched and present at higher fractions in
polyp tissue.
Discussion
Familial adenomatous polyposis, an autosomal dominant
colorectal tumor syndrome characterized by numerous
colorectal adenomatous polyps, is associated with an al-
most 100% lifetime risk of colorectal cancer if not de-
tected and removed. The majority of patients with FAP
harbor a germline mutation in the APC gene, and pa-
tients typically report family members with the same
condition, confirming its autosomal dominant
inheritance.
Approximately 10 to 25% of patients with FAP present
as sporadic cases [5, 6]. It has been widely recognized
that somatic mosaic mutation in APC is associated with
FAP and is more frequent than previously thought [5, 6,
8, 9]. Since the somatic mutation is invariably a de novo
event, patients with mosaic APC mutation typically have
no family history of FAP. Previous reports have
described enrichment of APC mutation from white
blood cells to colonic mucosa and adenomas, confirming
the critical role of mosaic mutation in tumorigenesis [5,
6, 8, 22].
In the present study, seven cases with mosaic APC
mutations were highly suspected to have FAP based on
endoscopic findings, but had no pathogenic variants in
genes known to be associated with this condition and no
family history of colonic polyposis. The mutation profile
of colon tissue was not verified in four patients, and
there is a high probability that the colonic lesions shared
the same mutation as blood cells. Considering the ecto-
dermal and endodermal origins of blood cells and
colonic epithelia, respectively, we presume that the mu-
tations in these cases occurred during early embryogen-
esis before separation of the two layers [5, 8, 23].
Because this process occurs before germ cell differenti-
ation, the presence of germ cells with the same mutation
Kim et al. BMC Medical Genomics          (2019) 12:103 Page 3 of 7
Ta
b
le
2
C
lin
ic
al
fe
at
ur
es
an
d
va
ria
nt
s
de
te
ct
ed
by
N
G
S
in
pa
tie
nt
s
w
ith
so
m
at
ic
AP
C
m
os
ai
ci
sm
ID
A
ge
at on
se
t
N
um
be
r
of po
ly
ps
C
ol
or
ec
ta
l
ca
rc
in
om
a
Fa
m
ily
hi
st
or
y
Sp
ec
im
en
M
ut
at
io
n
de
te
ct
ed
Va
ria
nt
ca
lle
rs
(v
ar
ia
nt
s
al
le
le
fre
qu
en
cy
)
M
ed
ia
n
de
pt
h
C
on
fir
m
at
io
n
te
st
H
C
M
uT
ec
t2
Va
rS
ca
n2
Pi
nd
el
P1
40
~
49
10
0
s
N
o
N
on
e
le
uk
oc
yt
e
c.
32
95
_3
29
6d
el
p.
Va
l1
09
9P
he
fs
Te
r1
9
N
D
0.
07
7
N
D
0.
06
8
26
68
M
EM
O
-P
C
R
P1
po
ly
p
c.
32
95
_3
29
6d
el
p.
Va
l1
09
9P
he
fs
Te
r1
9
0.
20
6
0.
20
6
0.
22
8
0.
19
7
79
0
P2
40
~
49
10
0
s
A
de
no
ca
rc
in
om
a
N
on
e
le
uk
oc
yt
e
c.
38
60
_3
86
1d
up
p.
G
ly
12
88
Te
r
N
D
0.
03
5
0.
09
4
0.
03
2
24
97
M
EM
O
-P
C
R
P3
30
~
39
20
0
s
N
o
N
on
e
le
uk
oc
yt
e
c.
35
77
_3
57
8d
el
p.
G
ln
11
93
Va
lfs
Te
r1
4
N
D
0.
00
3
N
D
0.
00
3
40
76
Ti
ss
ue
P4
50
~
59
50
–7
0
A
de
no
ca
rc
in
om
a
N
on
e
le
uk
oc
yt
e
c.
17
54
de
lT
p.
Le
u5
85
Pr
of
sT
er
5
N
D
0.
01
8
N
D
0.
02
0
29
60
P5
40
~
49
30
–5
0
N
o
M
at
er
na
lr
ec
ta
lc
an
ce
r
at
th
e
ag
e
of
70
le
uk
oc
yt
e
c.
69
4C
>
T
p.
A
rg
23
2T
er
N
D
0.
03
4
N
D
N
D
21
85
Ti
ss
ue
P6
40
~
49
20
–3
0
N
o
N
on
e
le
uk
oc
yt
e
c.
35
66
C
>
G
p.
Se
r1
18
9T
er
0.
11
4
0.
11
4
0.
11
4
N
D
36
24
Sa
ng
er
se
qu
en
ci
ng
P7
30
~
39
30
0
s
A
de
no
m
a
N
on
e
le
uk
oc
yt
e
c.
32
11
_3
23
8d
up
p.
G
lu
10
80
A
la
fs
Te
r1
0
0.
19
5
0.
27
5
N
D
0.
17
4
13
10
Sa
ng
er
se
qu
en
ci
ng
H
C
H
ap
lo
ty
pe
C
al
le
r,
M
EM
O
M
ut
an
t
en
ric
hm
en
t
w
ith
3′
-m
od
ifi
ed
ol
ig
on
uc
le
ot
id
es
,N
D
N
ot
de
te
ct
ed
Kim et al. BMC Medical Genomics          (2019) 12:103 Page 4 of 7
and transmission thereof to descendants cannot be ruled
out. Thus, genetic counseling is necessary, and children
of probands might require genetic testing.
APC somatic mosaicism is known to be associated
with both classical and attenuated FAP [5, 6]. In seven
patients with APC somatic mosaicism in this study, the
median age of onset was 45 years (range 31–53), while
that of patients with germline mutations was 34 years.
The number of polyps in patients with APC somatic mo-
saicism was round 100 or smaller, while patients with
classical FAP presented with more than 100 polyps [24].
Collectively, the patients with somatic mosaic APC mu-
tations tended to exhibit an attenuated phenotype.
Testing with NGS and analysis with MuTect2 and
Pindel algorithms detected low level mosaic mutations
of the APC gene that were assumed to cause the disease.
While somatic mosaic mutation of the APC gene has
recently been recognized, conventional sequencing
methods have limited sensitivity in the detection thereof.
Even with deep sequencing by NGS, variants with low
VAF might be missed if analyses are based on the
assumption that they are heterozygotes with an allele
frequency of at least 0.3. Care must be taken when
analyzing and interpreting hereditary cancer genes
known to be mutated in a mosaic pattern, such as APC
and PPM1D [25, 26]. The possibility of low-level mosaic
mutation should be considered.
There are several previous reports on the detection of
somatic mosaic mutations of the APC gene [5–11]. To
detect low-level mutant alleles, various methods have
been used, including denaturing high-performance liquid
chromatography, protein truncation test, and high-
resolution melting analysis [5–7]. These are less feasible
to apply in routine genetic testing for hereditary cancer.
We produced sequencing data in a single assay and ana-
lyzed them with several algorithms to detect low level
Fig. 1 Visual verification of variants with Integrative Genomic Viewer (IGV) and sequencing chromatogram with secondary confirmation test results.
Variants with low fractions in IGV reflect NGS results from analyzing peripheral blood. The corresponding sequencing chromatograms are the results of
MEMO-PCR of peripheral blood for P1 and P2, conventional PCR of polyp tissue for P3 and P5, and conventional PCR of peripheral blood for P6 and P7
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variants. GATK HaplotypeCaller is widely used to iden-
tify germline variants, and MuTect2 and VarScan2 are
optimized to identify variants in cancer specimens [14,
18, 19]. Pindel is a split-read analysis tool for medium to
large indels [20]. Among the four variant callers used,
only MeTect2 and Pindel could detect low-level mosaic
pathogenic variants, with VAFs of 0.2–0.8%. The NGS
method has a sensitivity of 10− 5~10− 6 with adequate
sequencing quality and sequencing depth. In addition to
adequate analytic tools, it is worth emphasizing the im-
portance of sufficient read depth and careful visual veri-
fication to distinguish true variants because tools used
to detect low-level variants tend to produce more false
positive results.
Conclusions
We confirmed the clinical utility of NGS testing with ad-
equate combination of bioinformatics tools in detecting
low-level somatic variants and deletions in a single assay.
We also discovered that mosaic APC mutation may be
more frequent than previously thought. Accordingly, the
presence of mosaic mutation should be considered when
analyzing genetic tests in patients with FAP.
Additional file
Additional file 1: Table S1. Genes included in the hereditary cancer
panel. Table S2. Primers used in the MEMO-PCR to confirm low-level var-
iants in APC. Table S3. Pathogenic or likely pathogenic germline APC vari-
ants in patients suspicious for familial adenomatous polyposis. Table S4.
All variants identified from NGS hereditary cancer panel. (DOCX 58 kb)
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